R&G PharmaStudies Co., Ltd. (SHE:301333)
China · Delayed Price · Currency is CNY 78.07
-0.28 (-0.36%)
At close: Feb 12, 2026
R&G PharmaStudies Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Net Income | 151.37 | 140.22 | 162.53 | 113.45 | 99.24 | 83.84 |
Depreciation & Amortization | 20.74 | 20.74 | 34.57 | 19.03 | 36.05 | 6.47 |
Other Amortization | 16.97 | 16.97 | 2.19 | 17.4 | 1.59 | 17.8 |
Loss (Gain) From Sale of Assets | 0.07 | 0.07 | 0.02 | 0.02 | 0.02 | 0 |
Asset Writedown & Restructuring Costs | - | - | 0 | - | - | 0.04 |
Loss (Gain) From Sale of Investments | -24.95 | -24.95 | -27.44 | -9.14 | -2.6 | -3.49 |
Provision & Write-off of Bad Debts | 3.36 | 3.36 | 4.86 | 3.57 | 7.54 | 5.09 |
Other Operating Activities | -77.16 | 4.96 | 0.23 | -3.56 | 3.29 | 5.21 |
Change in Accounts Receivable | -54.95 | -54.95 | -20.08 | -42.52 | -58.34 | -45.51 |
Change in Inventory | -4.23 | -4.23 | 1.75 | -9.74 | -14.6 | -4.69 |
Change in Accounts Payable | 52.19 | 52.19 | 21.66 | 42.55 | 43.5 | -21.6 |
Change in Other Net Operating Assets | -0.02 | -0.02 | 13.27 | 0.22 | 0.36 | 1.13 |
Operating Cash Flow | 83.79 | 154.76 | 192.56 | 130.47 | 114.57 | 44.1 |
Operating Cash Flow Growth | -50.36% | -19.63% | 47.60% | 13.87% | 159.80% | -57.38% |
Capital Expenditures | -24.03 | -19.98 | -19.88 | -20.83 | -38.28 | -25.48 |
Sale of Property, Plant & Equipment | 0.01 | 0.01 | 0.02 | 0.15 | 0.09 | 0.14 |
Cash Acquisitions | -24 | -21.31 | - | - | - | - |
Investment in Securities | 113.13 | -26 | -710 | - | - | - |
Other Investing Activities | 22.41 | 22.95 | 25.05 | 9.14 | 2.6 | 3.49 |
Investing Cash Flow | 87.53 | -44.33 | -704.8 | -11.54 | -35.59 | -21.86 |
Short-Term Debt Issued | - | 54.79 | - | - | - | - |
Total Debt Issued | - | 54.79 | - | - | - | - |
Long-Term Debt Repaid | - | -14.36 | -12.74 | -11.5 | -9.94 | - |
Net Debt Issued (Repaid) | -69.5 | 40.43 | -12.74 | -11.5 | -9.94 | - |
Issuance of Common Stock | 15.19 | 15.18 | - | 1,114 | - | - |
Repurchase of Common Stock | -56.09 | -56.09 | - | - | - | - |
Common Dividends Paid | -15.7 | -28.38 | -5.82 | - | - | - |
Other Financing Activities | 53.3 | -19.87 | - | -66.99 | - | 0.7 |
Financing Cash Flow | -72.81 | -48.74 | -18.56 | 1,036 | -9.94 | 0.7 |
Foreign Exchange Rate Adjustments | 1.31 | 1.76 | 1.1 | 5.44 | -1.27 | -3.52 |
Net Cash Flow | 99.82 | 63.44 | -529.69 | 1,160 | 67.77 | 19.43 |
Free Cash Flow | 59.76 | 134.78 | 172.68 | 109.64 | 76.29 | 18.62 |
Free Cash Flow Growth | -60.61% | -21.95% | 57.50% | 43.71% | 309.66% | -75.96% |
Free Cash Flow Margin | 7.57% | 18.12% | 23.94% | 17.20% | 12.54% | 3.84% |
Free Cash Flow Per Share | 0.63 | 1.41 | 1.80 | 1.33 | 1.06 | 0.26 |
Cash Income Tax Paid | 53.82 | 49.53 | 55.1 | 40.9 | 45.16 | 36.74 |
Levered Free Cash Flow | 67.35 | 116.07 | 133.19 | 80.6 | 44.54 | -6.99 |
Unlevered Free Cash Flow | 69.28 | 118.22 | 133.56 | 81.02 | 44.9 | -6.99 |
Change in Working Capital | -6.62 | -6.62 | 15.6 | -10.3 | -30.55 | -70.87 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.